BACKGROUND: The place of monoclonal antibodies in metastatic colorectal cancer has not been clearly defined. OBJECTIVE: To determine the treatment pattern of monoclonal antibodies in colorectal cancer patients in the Andalusian Public Healthcare System. METHOD: Data were collected from all patients treated with these drugs from July 2009 to December 2010 from pharmacy programs and medical records. RESULTS: Three hundred patients were included, of whom 227 received the antibody at the forefront. The proportion of patients who received bevacizumab in the first line is greater than that of cetuximab (62.1 vs. 37.5 % respectively) and similar in the second line and subsequent (47.8 vs. 53.8 % and 48.5 vs. 46.2 % respectively). XELOXbevacizumab was the most frequently prescribed scheme (35.3 %) followed by FOLFOX-monoclonal antibody schemes, regardless that this was bevacizumab or cetuximab (22.5 %). The median progression free survival (PFS) was 11.7 months for patients receiving cetuximab, 9.6 months for patients receiving bevacizumab and 8.2 months for those who received no monoclonal antibody in the first line. CONCLUSION: Bevacizumab was the antibody of choice in first line, showing utilization rates similar to cetuximab in second line and subsequent. The median PFS in our study is related to the PFS of the major clinical trials.
BACKGROUND: The place of monoclonal antibodies in metastatic colorectal cancer has not been clearly defined. OBJECTIVE: To determine the treatment pattern of monoclonal antibodies in colorectal cancerpatients in the Andalusian Public Healthcare System. METHOD: Data were collected from all patients treated with these drugs from July 2009 to December 2010 from pharmacy programs and medical records. RESULTS: Three hundred patients were included, of whom 227 received the antibody at the forefront. The proportion of patients who received bevacizumab in the first line is greater than that of cetuximab (62.1 vs. 37.5 % respectively) and similar in the second line and subsequent (47.8 vs. 53.8 % and 48.5 vs. 46.2 % respectively). XELOXbevacizumab was the most frequently prescribed scheme (35.3 %) followed by FOLFOX-monoclonal antibody schemes, regardless that this was bevacizumab or cetuximab (22.5 %). The median progression free survival (PFS) was 11.7 months for patients receiving cetuximab, 9.6 months for patients receiving bevacizumab and 8.2 months for those who received no monoclonal antibody in the first line. CONCLUSION:Bevacizumab was the antibody of choice in first line, showing utilization rates similar to cetuximab in second line and subsequent. The median PFS in our study is related to the PFS of the major clinical trials.
Authors: M Julieta Corral; Ana Clopès; Matilde Navarro; Josep Ramon Germà; Josep Maria Borràs Journal: Med Clin (Barc) Date: 2007-06-23 Impact factor: 1.725
Authors: Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello Journal: J Clin Oncol Date: 2011-04-18 Impact factor: 44.544
Authors: Zhongyun Zhao; Elise Pelletier; Beth Barber; Monali Bhosle; Song Wang; Sue Gao; David Klingman Journal: Curr Med Res Opin Date: 2012-01-17 Impact factor: 2.580
Authors: Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy Journal: J Clin Oncol Date: 2008-04-20 Impact factor: 44.544
Authors: Charles S Fuchs; John Marshall; Edith Mitchell; Rafal Wierzbicki; Vinod Ganju; Mark Jeffery; Joseph Schulz; Donald Richards; Raoudha Soufi-Mahjoubi; Benjamin Wang; José Barrueco Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Daniel J Sargent; Claus Henning Köhne; Hanna Kelly Sanoff; Brian M Bot; Matthew T Seymour; Aimery de Gramont; Ranier Porschen; Leonard B Saltz; Philippe Rougier; Christopher Tournigand; Jean-Yves Douillard; Richard J Stephens; Axel Grothey; Richard M Goldberg Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Mark Kozloff; Marianne Ulcickas Yood; Jordan Berlin; Patrick J Flynn; Fairooz F Kabbinavar; David M Purdie; Mark A Ashby; Wei Dong; Mary M Sugrue; Axel Grothey Journal: Oncologist Date: 2009-09-02